Zacks Investment Research upgraded shares of Catasys (NASDAQ:CATS) from a hold rating to a buy rating in a research note issued to investors on Thursday morning. They currently have $13.00 target price on the stock.
According to Zacks, “Catasys, Inc., formerly known as Hythiam, Inc., provides specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Company’s program seeks to improve member health by delivering medical and psychosocial interventions in combination with long term care coaching, including their proprietary treatment program for alcoholism and stimulant dependence. Catasys, Inc. is based in Los Angeles. “
CATS has been the topic of several other reports. TheStreet raised Catasys from an e+ rating to a c rating in a research note on Thursday, November 29th. ValuEngine raised Catasys from a buy rating to a strong-buy rating in a research note on Tuesday, October 2nd. Finally, Canaccord Genuity boosted their price objective on Catasys from $12.00 to $15.00 and gave the stock a buy rating in a research note on Wednesday, September 26th.
Catasys (NASDAQ:CATS) last issued its quarterly earnings data on Wednesday, November 14th. The company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.02. Catasys had a negative return on equity of 546.50% and a negative net margin of 122.75%. The company had revenue of $4.37 million for the quarter, compared to analysts’ expectations of $4.00 million. As a group, analysts predict that Catasys will post -1.05 EPS for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in shares of Catasys by 205.5% during the third quarter. JPMorgan Chase & Co. now owns 10,418 shares of the company’s stock valued at $134,000 after buying an additional 7,008 shares during the last quarter. Engineers Gate Manager LP bought a new position in shares of Catasys during the third quarter valued at approximately $139,000. Ancora Advisors LLC bought a new position in shares of Catasys during the third quarter valued at approximately $191,000. B. Riley Wealth Management Inc. bought a new position in shares of Catasys during the third quarter valued at approximately $217,000. Finally, Vanguard Group Inc grew its stake in shares of Catasys by 53.8% during the third quarter. Vanguard Group Inc now owns 171,813 shares of the company’s stock valued at $2,208,000 after buying an additional 60,090 shares during the last quarter. 11.14% of the stock is currently owned by hedge funds and other institutional investors.
Catasys Company Profile
Catasys, Inc provides big data predictive analytics, artificial intelligence and telehealth, combined with human intervention services to health plans and other third party payors. It offers OnTrak solution to improve treatment outcomes and lower the utilization of medical and behavioral health plan services.
Featured Article: Penny Stocks, What You Need To Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catasys and related companies with MarketBeat.com's FREE daily email newsletter.